Ftse Mib
34.000,65
1,10%
DAX
18.178,27
1,03%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
0,00%
Bitcoin
64.167,26
0,26%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Celgene Corporation (CELG) Celgene Corporation (CELG) Notizie

CELG

Celgene (CELG)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CELG
DataOraFonteTitoloSimboloCompagnia
16/12/201913:30GlobeNewswire Inc.NexImmune Appoints Sol Barer as Chairman of the Board of DirectorsNASDAQ:CELGCelgene Corporation
21/11/201912:21PR Newswire (US)Amgen Completes Acquisition Of Otezla® (apremilast)NASDAQ:CELGCelgene Corporation
20/11/201922:18Business WireCelgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...NASDAQ:CELGCelgene Corporation
20/11/201920:09Business WireCELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...NASDAQ:CELGCelgene Corporation
19/11/201917:16PR Newswire (US)Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500NASDAQ:CELGCelgene Corporation
18/11/201923:10GlobeNewswire Inc.Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019NASDAQ:CELGCelgene Corporation
15/11/201923:39Dow Jones NewsFTC Requires Bristol-Meyers Squibb, Celgene to Divest Otezla as Condition of AcquisitionNASDAQ:CELGCelgene Corporation
15/11/201914:22Dow Jones NewsCelgene Gets CHMP Positive Opinion for Revlimid/Rituximab Combo in Follicular LymphomaNASDAQ:CELGCelgene Corporation
15/11/201913:30Business WireCelgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...NASDAQ:CELGCelgene Corporation
13/11/201904:28PR Newswire (Canada)Skyhawk Therapeutics annonce une deuxième entente de collaboration multicible avec Celgene pour découvrir et mettre au poin...NASDAQ:CELGCelgene Corporation
12/11/201915:00PR Newswire (US)Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small...NASDAQ:CELGCelgene Corporation
08/11/201919:30Dow Jones NewsAcceleron Pharma Shares Gain Ground After FDA Approves ReblozylNASDAQ:CELGCelgene Corporation
08/11/201919:20Dow Jones NewsFDA Approves Celgene's and Acceleron's Reblozyl to Treat Rare Blood DisorderNASDAQ:CELGCelgene Corporation
08/11/201918:33Business WireFDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...NASDAQ:CELGCelgene Corporation
06/11/201922:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CELGCelgene Corporation
06/11/201915:06Business WireCelgene to Present New & Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annua...NASDAQ:CELGCelgene Corporation
31/10/201921:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CELGCelgene Corporation
31/10/201912:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CELGCelgene Corporation
31/10/201912:30Business WireCelgene Reports Third Quarter 2019 Operating and Financial ResultsNASDAQ:CELGCelgene Corporation
16/10/201912:00Business WireCelgene & the Multiple Sclerosis Association of America Take the MS MindShift Initiative & “Brain Bulb” Hot Air Balloon t...NASDAQ:CELGCelgene Corporation
20/09/201913:30Business WireCelgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant RecipientsNASDAQ:CELGCelgene Corporation
12/09/201922:30Business WireCelgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myel...NASDAQ:CELGCelgene Corporation
11/09/201918:24Dow Jones NewsSwiss Biotech Anokion Raises $40 Million in Series B RoundNASDAQ:CELGCelgene Corporation
09/09/201913:30Business WireData from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress...NASDAQ:CELGCelgene Corporation
27/08/201909:02Dow Jones NewsCelgene, Bristol Clear Way For Merger -- WSJNASDAQ:CELGCelgene Corporation
26/08/201917:14Dow Jones NewsAmgen to Buy Celgene's Otezla for $13.4 Billion--UpdateNASDAQ:CELGCelgene Corporation
26/08/201913:49Dow Jones NewsAmgen to Buy Celgene's Otezla for $13.4 Billion -- UpdateNASDAQ:CELGCelgene Corporation
26/08/201913:14Dow Jones NewsAmgen to Buy Celgene's Otezla for $13.4 BillionNASDAQ:CELGCelgene Corporation
26/08/201912:30PR Newswire (US)Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefi...NASDAQ:CELGCelgene Corporation
21/08/201914:45InvestorWireRecord Revenues, Milestone Achievements Indicate Strength, Potential of Biotech SectorNASDAQ:CELGCelgene Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CELG

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
AMP
Amplifon
BIT
BAMI
Banco BPM
BIT
LDO
Leonardo
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
TRN
Terna Trasmissione Elett...
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network